Sep 2026· Chinese Medical Journal - Pulmonary and Critical Care Medicine· Vol 4, pp. 235 - 249· 0 citations· 124 references
Medicine
TL;DR
The current progress in cell therapy for lung cancer is summarized, key challenges are analyzed, and potential solutions are proposed.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Over the past decade, immunotherapy, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) or cytotoxic T lymphocyte associated antigen-4 (CTLA-4), has revolutionized the treatment paradigm of lung cancer, reducing the risk of death by approximately 30%. However, approximately 70% of patients with advanced non-small cell lung cancer are either non-responsive to ICIs or initially respond to treatment but eventually experience disease progression due to acquired resistance. This subset of non-responsive or ultimately resistant patients is often characterized by complete exhaustion of endogenous anti-tumor T cells, which are unable to exert anti-tumor effects, thereby leading to ICI non-response or resistance. Correspondingly, the adoptive transfer of immune cells has shown promising efficacy in numerous clinical studies involving this patient population. Nevertheless, the Food and Drug Administration (FDA) has not yet approved any cell therapy strategy for lung cancer, primarily because of factors such as the hostile tumor microenvironment and T cell exhaustion. Herein, we summarize the current progress in cell therapy for lung cancer, analyze key challenges, and propose potential solutions.
Evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods is highlighted, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration.
Seong-Ah Shin, Minji Kim, Moonsu Kim et al.· Life· 0 citations
Data from preclinical models and clinical trials indicate that PD-1 inhibition helps exhausted CAR-T cells recover function, shifts the TME away from an immunosuppressive state, and supports epitope spreading; together these effects strengthen antitumor activity and may lower relapse rates.
Jia-Qi Hu· Theoretical and Natural Scie...· 0 citations
Overall, ICI resistance in GU cancers emerges as a multidimensional phenomenon with distinct biological drivers across tumor subtypes; precision combinations targeting both intrinsic tumor factors and the immunosuppressive TME represent the most promising avenue to overcome resistance, and standardization of composite...
Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain...
Lu-Ke Ding, Anna Staskiewicz, Jesse Kao et al.· Frontiers in Pharmacology· 0 citations
Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer cell vaccine (GVAX)....
Chen Qing, E. Ghorani, K. Foster et al.· Cancer immunology research· 0 citations
This review examines lineage plasticity, epigenetic regulation, defective antigen presentation, defective antigen presentation, and altered DNA sensing and interferon responses that interact with T-cell dysfunction, suppressive myeloid populations, and organ-specific niches.